IDEXX Laboratories Inc

Healthcare · Diagnostics & Research

522.00$ +0.1% vs. previous close Closing price · As of: Sep 23, 2026

Statements

Balance Sheet

IDEXX Laboratories Inc (IDXX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Total Assets" came in at 3,351 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet IDXX
Line item	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Total Assets	374	377	391	360	336	373	417	522	514	491	560	702	765	809	897	1,031	1,104	1,231	1,384	1,475	1,531	1,713	1,537	1,832	2,295	2,437	2,747	3,260	3,293	3,351
Current Assets	302	274	263	232	216	236	289	371	302	299	302	306	356	376	461	524	570	653	759	822	846	972	654	680	1,063	956	1,101	1,495	1,400	1,340
Cash	128	107	109	59	46	67	114	187	47	67	62	60	79	107	157	184	224	279	323	129	155	188	124	90	384	144	113	454	288	180
Cash & Short-Term Investments	128	107	109	59	75	80	147	221	137	133	97	60	79	107	157	184	224	279	323	343	392	472	124	90	384	144	113	454	288	180
Receivables	67	47	48	58	57	51	46	54	66	72	81	108	111	115	120	141	138	158	181	200	232	270	259	307	375	426	491	530	474	693
Inventory	48	60	55	48	66	86	75	75	76	69	96	99	116	110	128	133	141	133	160	189	158	164	173	195	210	269	368	380	382	378
Property, Plant & Equipment	–	–	–	–	46	49	49	45	63	66	100	142	190	200	202	217	245	281	304	333	357	379	437	534	555	588	649	–	–	–
Goodwill	–	–	–	–	–	–	52	55	93	88	105	236	139	149	149	173	175	181	184	179	178	200	214	240	243	359	362	366	405	414
Intangible Assets	–	–	–	–	–	–	56	62	124	31	43	236	68	64	56	69	63	59	65	56	46	44	42	58	53	99	98	85	112	110
Total Liabilities	51	74	83	76	74	71	76	109	117	121	150	264	327	294	323	491	467	712	1,267	1,559	1,639	1,767	1,547	1,655	1,662	1,747	2,138	1,775	1,698	1,745
Current Liabilities	51	74	79	76	74	71	76	101	100	107	125	223	295	256	285	437	406	478	821	857	935	1,005	770	725	583	764	1,236	952	1,068	1,149
Short-Term Debt	3.0	4.1	5.2	3.5	8.5	8.4	1.0	0.9	1.3	0.6	0.7	73	151	120	130	244	213	278	549	573	611	655	399	304	68	168	674	345	168	500
Accounts Payable	19	13	27	22	14	11	9.4	19	15	20	24	33	28	19	23	37	35	30	45	53	60	67	70	72	75	116	110	111	114	110
Long-Term Debt	–	–	–	–	–	–	–	–	0.5	–	6.4	5.7	5.1	4.3	3.4	2.5	1.4	150	350	597	593	606	601	699	858	775	694	623	450	375
Shareholders' Equity	323	303	308	284	262	302	341	413	398	369	410	438	438	515	574	540	636	518	118	-84	-108	-54	-9.5	177	632	690	609	1,485	1,595	1,605
Retained Earnings	67	46	31	64	100	138	183	240	319	397	491	586	702	824	966	1,127	1,306	1,493	1,675	318	540	804	1,168	1,596	2,176	2,920	3,600	4,445	5,332	6,392
Shares Outstanding	157	151	152	159	144	139	140	144	143	136	132	129	124	121	119	116	112	108	102	94	91	90	88	88	87	87	85	84	83	81

Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings